> Xoma and Schering-Plough have extended their collaboration to develop antibodies for cancer and immune diseases. Release
> Sirion Therapeutics has licensed the U.S. marketing rights to Labatoires Thea's topical ophthalmic gel for eye infections. Report
> Molecular Insight Pharmaceuticals has entered into a worldwide, exclusive licensing agreement with Bayer Schering Pharma to acquire ZK-BA, a compound in development for the treatment of malignant melanoma. Release
> Cepheid and bioMerieux are teaming up to develop tests that identify biomarkers for antibiotic resistance as well as bacteria and fungi. Report
> BG Medicine is collaborating with Applied Biosystems in the discovery and development of biomarkers. BG brings its expertise in biology while Applied Systems contributes the instruments and software. Report
> Wellbutrin XR has been approved for marketing in The Netherlands, the first European approval for the drug. Report
And Finally… Fewer smokers, earlier detection and better therapies are listed as the three primary reasons for a decline in the number of cancer deaths in the U.S. In 2004 the number of cancer deaths dropped by 3,014 after dropping a few hundred the year before. This is the first time since 1930 that cancer deaths have declined. Article